VANCOUVER, BC, May 6, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that its North American autism clinical study has been listed on ClinicalTrials.gov (NCT04869930), a database of privately and publicly funded clinical studies conducted around the world.
The US-based Observational Study, NM101: Establishing a Diagnostic and Therapeutic Index in Autism Spectrum Disorder (ASD) and Fragile X Syndrome (FXS) is a large-scale effort to examine the dynamic roles of microbiota, serotonin signaling and the immune system in gut and brain development of ASD and FXS, particularly as these forces work together to manifest classic behavioral symptoms. AI-driven computational analysis of collected datasets will be used to establish a “Diagnostic and Therapeutic Index (ASD-DTI)” – an objective set of tools that can help differentiate subtypes of ASD and develop more accurate methods of diagnosis and response to drug treatment.
“We are developing this set of multidimensional biomarkers to help differentiate subsets of symptomatic, as well as pre-symptomatic, ASD and FXS patients – an approach that currently does not exist in clinical practice,” stated Julia V. Perederiy, PhD, NOVA’s Lead Scientist and Principal Investigator on the study. “Furthermore, we will use the index to subsegment participants in upcoming Phase 1 and Phase 2 clinical trials of NOVA’s proprietary psilocybin formulation – an essential step for study design and development of hard endpoints to corroborate clinical results.”
NOVA aims to recruit at least 300 participants across the U.S and Canada: 200+ with diagnosed ASD or FXS and 100+ neurotypical controls, including pre-symptomatic/undiagnosed children under age 5. Participants will be asked to provide samples of cheek cells, urine, finger/toe-prick blood and feces, which will be used to quantify serotonin levels and related cell signaling pathways, as well as evaluate commensal bacterial species and their function in the gut. Samples will be compared with those from age-matched neurotypical controls.
The study has been approved by an Institutional Review Board (IRB) in the United States, with planned expansion of the approval into Canada in the near future. IRBs are ethics committees designed to help regulatory agencies ensure that companies employ rigorous protocol standards and adhere to strict regulations surrounding the ethical treatment of human subjects. The study’s data collection and storage protocols are also compliant under the Health Insurance Portability and Accountability Act (HIPAA), which sets the standard for protection of sensitive patient data.
ClinicalTrials.gov is a web-based resource that provides patients, their family members, health care professionals, researchers and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions. The web site is maintained by the National Library of Medicine (NLM) at the National Institutes of Health (NIH).
NOVA’s ClinicalTrials.gov Identifier is: NCT04869930: https://clinicaltrials.gov/ct2/show/NCT04869930
For more information about the study, please email email@example.com or call 1-888-505-NOVA.
Sign up for MORE news updates !
This article is written and published by The Cannabis Stock
Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies
The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.